CN117500795A - 受体相互作用蛋白1抑制剂、其制备及用途 - Google Patents

受体相互作用蛋白1抑制剂、其制备及用途 Download PDF

Info

Publication number
CN117500795A
CN117500795A CN202280022439.7A CN202280022439A CN117500795A CN 117500795 A CN117500795 A CN 117500795A CN 202280022439 A CN202280022439 A CN 202280022439A CN 117500795 A CN117500795 A CN 117500795A
Authority
CN
China
Prior art keywords
compound
tautomer
pharmaceutically acceptable
acceptable salt
deuterated derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022439.7A
Other languages
English (en)
Chinese (zh)
Inventor
苏亚宁
张朝兰
徐彦平
张志远
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viteron Co ltd
Original Assignee
Viteron Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viteron Co ltd filed Critical Viteron Co ltd
Publication of CN117500795A publication Critical patent/CN117500795A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202280022439.7A 2021-03-18 2022-03-17 受体相互作用蛋白1抑制剂、其制备及用途 Pending CN117500795A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021081514 2021-03-18
CNPCT/CN2021/081514 2021-03-18
PCT/CN2022/081544 WO2022194259A1 (en) 2021-03-18 2022-03-17 Receptor-interacting protein 1 inhibitors, preparations, and uses thereof

Publications (1)

Publication Number Publication Date
CN117500795A true CN117500795A (zh) 2024-02-02

Family

ID=83321909

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022439.7A Pending CN117500795A (zh) 2021-03-18 2022-03-17 受体相互作用蛋白1抑制剂、其制备及用途

Country Status (7)

Country Link
US (1) US20240217963A1 (https=)
EP (1) EP4308555A4 (https=)
JP (1) JP2024512931A (https=)
CN (1) CN117500795A (https=)
CA (1) CA3209628A1 (https=)
IL (1) IL305530A (https=)
WO (1) WO2022194259A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233544A1 (en) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof
CN121487930A (zh) 2023-05-10 2026-02-06 建新公司 作为ripk1抑制剂的异噁唑烷及其用途
CN121079291A (zh) 2023-05-10 2025-12-05 建新公司 作为ripk1抑制剂的异噁唑烷及其使用
CN120607513A (zh) * 2024-03-08 2025-09-09 山东全重生物医药科技有限公司 Ripk1抑制剂、其制备方法及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097474A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2012052948A1 (en) * 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
WO2020103859A1 (en) * 2018-11-20 2020-05-28 Sironax Ltd RIP1 Inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637620A1 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
ES2404580T3 (es) * 2007-10-11 2013-05-28 Glaxosmithkline Llc Novedosos inhibidores de la ehs y uso de los mismos
HUE039922T2 (hu) * 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
WO2016101885A1 (en) * 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
EP3224245B1 (en) * 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
TWI730959B (zh) * 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
TW201831464A (zh) * 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
SG11202105250TA (en) * 2018-11-20 2021-06-29 Sironax Ltd Cyclic Ureas
KR20200087922A (ko) * 2019-01-11 2020-07-22 보로노이바이오 주식회사 (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097474A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2012052948A1 (en) * 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
WO2020103859A1 (en) * 2018-11-20 2020-05-28 Sironax Ltd RIP1 Inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS: "STN检索报告", STN REGISTRY 数据库, 19 May 2017 (2017-05-19), pages 1 - 9 *

Also Published As

Publication number Publication date
US20240217963A1 (en) 2024-07-04
IL305530A (en) 2023-10-01
CA3209628A1 (en) 2022-09-22
EP4308555A1 (en) 2024-01-24
JP2024512931A (ja) 2024-03-21
WO2022194259A1 (en) 2022-09-22
EP4308555A4 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
CN113365995B (zh) 免疫调节剂，组合物及其方法
KR102563325B1 (ko) Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
CN117500795A (zh) 受体相互作用蛋白1抑制剂、其制备及用途
CN112771027B (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CA3085561A1 (en) Cyclohexyl acid triazole azines as lpa antagonists
JP2020525522A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
EA039808B1 (ru) Аминотриазолопиридины в качестве ингибиторов киназ
CN114423751B (zh) 用作选择性aurora a抑制剂的新型杂环化合物
IL240048A (en) Compounds with a large number of heteroyls as pgds-h inhibitors and their use in the treatment of prostaglandin-mediated diseases 2d
JP2025516367A (ja) Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
CN116903605A (zh) 一种kif18a抑制剂及其用途
AU2016279965A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
CN117645606A (zh) 受体抑制剂、包含其的药物组合物及其用途
KR102920599B1 (ko) 항종양 활성을 갖는 화합물 및 이의 용도
CN115843297A (zh) 作为bcl-2抑制剂的化合物
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
WO2023177593A1 (en) Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor
WO2022155419A1 (en) Indazoles and azaindazoles as lrrk2 inhibitors
AU2009230130A1 (en) Hydroxyquinoxalinecarboxamide derivative
US11970493B2 (en) Autotaxin inhibitor compounds
EP3904348A1 (en) Aminopyridine compound, preparation method therefor and use thereof
JP2025521507A (ja) 置換縮合二環式化合物および関連する治療方法
HK40107958A (zh) 受体相互作用蛋白1抑制剂、其制备及用途
KR20260022448A (ko) 디히드로피리미딘-2,4(1h,3h)-디온을 함유하는 폴리시클릭 유도체 및 이의 약학적 조성물, 이의 제조 방법 및 이의 용도
CN121335899A (zh) 异吲哚啉酮和二氢吡咯并吡啶酮化合物以及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107958

Country of ref document: HK